Psychiatric Drug Effects
Home > Pharmacogenetics


Pharmacogenetics determines each person's functional ability to metabolise and excrete prescribed drugs; the efficacy of medication is determined by natural human genetic variations which influence peoples response to medication.

Psychotropic drugs are metabolised through various sites and systems in the body. One major site is the CYP 450 Cytochrome family, which are found primarily in the liver.

75% of all psychotropic drugs are metabolised through the CYP2D6 and 15% through the CYPC19 pathway.

Pharmacogenetics has been known and used by pharmaceutical companies for many years. Drug trials are conducted on people who are specifically selected for their efficiency for metabolising each specific drug. This enables pharmaceutical companies to show the best possible outcome for the new drug; this has the potential for minimising adverse reactions and side effects.

Adverse reactions and side effects are exhibited by people who have the genetic inability to metabolise the drug efficiently.

Genotyping is a blood test or buccal swab test for the CYP Family and can determine a persons ability to metabolise a drug. Different neuroleptic drugs are metabolised through different pathways.

For each CYP450 pathway, persons are classified into one of four groups.

Poor Metabolisers (PM)
Intermediate Metaboliser (IM)
Extensive Metaboliser (EM)
Ultra Extensive Metaboliser (UM)

Poor Metabolisers (PM)
When a person depicts little or no enzyme activity for the cytochrome pathway, a neuroleptic or antidepressant drug normally metabolised through this pathway would reach higher concentrations in the blood stream and take longer to clear. The toxicities of chemicals escalate in the body, resulting in drug induced side effects due to decreased drug elimination. The recommendation for PM is that patients need to avoid drugs which require that specific pathway. Drugs prescibed to PMs are not therapeutic.  

Intermediate Metaboliser (IM)
With IMs side effects take longer to appear due to the slower build up of drug concentrations.  Drugs prescibed to IMs are not therapeutic.  

Extensive Metaboliser (EM)
EMs have no side effects and the standard dose is therapeutic. 

Ultra Extensive Metaboliser (UM)
UMs are ultra quick metabolisers and the standatrd dose is not therapeutic. UMs may require an increased dose because of the higher rate of metabolism. BUT in the case of prodrug use, drug toxicities raidly occur.

Persons vary tremendously with their genetic functioning.  7-14% Caucasians are Poor Metabolisers and 75% of all psychotrophic drugs metabolised through CYP2D6. Further information on the genetic efficacy for ethnic groups, together with more extensive details on genetic testing: 

Persons who are PMs, IMs and UMs for prodrugs  will experience an increase of neurotoxic behavioural conditions such as akathisia, insomnia, mania, delusions, hallucinations, serotonin syndrome, psychosis, suicide and suicidality and homidie and homicide ideation. 

These psychiatric drug induced conditions are toxic and need to be recognised as such as stated in the DSM IV and are NOT to be confused with fucntional conditions. However if the above psychological conditions are functional, if patients are inefficient metabolisers and treated with psychiatric drugs, thier mental health will deteriorate.    

The wider picture and implications are many.

In my experience many clinicians within mental health are naive about the genetic inability to metabolise psychotropic drugs and therefore many patients have the potential of being misdiagnosed.  For example a person who poorly metabolises the SSRI Prozac drug, has the potential for exhibiting manic psychotic symptoms and will be undoubtedly interpreted by many psychiatrists as ’schizophrenic’. Many professionals have the potential of unwittingly perpetuating patients’ suffering, resulting from psychotropic iatrogenic conditions. The legally sectioned patients are incredibly vulnerable, as they have no choice about taking neuroleptic drugs.

I think there is a professional requirement for each patient to be given the genotyping test prior to prescriber's' writing psychotropic prescriptions; I consider this precautionary measure would show professional responsibility in safe guarding patients from acquiring potentially dangerous toxic levels whilst within their care.

Many clinicians have abdicated responsibility for patients’ medication, stating this is the sole responsibility of the prescriber. I disagree. The impact of psychotropic drugs on patients’ affects the effectiveness of each clinicians' expertise and I perceive each team member equally responsible of the patients psychological and physical well being. Since many professionals work in multidisciplinary teams, each team member is equally responsible in working collaboratively together and needs to be aware of genotyping with its potential detrimental implications for patients. ‘Medicines management is everyone’s business’ NWW Pamphlet

In the NHS genotyping is available within general medicine to patients to assess efficacy for drugs, for disease such as Rheumatoid Arthritis, HIV, cancer and Crohn’s disease.  There is no patient charge for this genotyping test.

The NICE Guidelines have been aware of pharmacogenetics since 2006, when I introudced the issue at a NWW pharmacy meeting. Subsequently the material provided at the time was archived because of potential costs. With further information supplied to NICE pharmacogenetics is reviewed and and may incorporate pharmaocgenetics into furter guidelines.  (2016)

Meanwhile neither patients, doctors and carers are left without a fully informed choice about taking psychotropic drugs.

Genotyping test can be purchased by patients and carers through Genelex USA. Gelelx does not require a doctors  reference and the results are sent direclty to the customer.

In addition to the inner psychological torment and the downward physical spiral when patients are PM and IMs many patients are trapped withijn a viscious cycle of non therapeutic and damaging drugs; Patients are either destroyed, dead or walking dead. 

Considering the NHS cost of maintaining persons with mental health difficulties, the inability to metabolise efficiently needs to be addressed; long-term maintenance in the mental health system is not cost effective. 

When pharmacogenetics come to the forefront of Mental Health, conflicts of interests may arise, which need to be taken into account, bearing in mind Mental Health practitioners are in their chosen professional to be of service to their patients who are primarily the consumers.

The denial of leading mental health clinicians in implementing the genotyping test for those people who are clearly suffering from inappropriate neuroleptic medication I think is unethical and immoral.

One psychiatrist described Clozapine the 'golden wonder drug'; I thought more like  'golden poison'. An emotive word to use but the reality is that antipsychotics are neurotoxic and to perpetuate neurotoxicites ad infinitum within vulnerable people, particularly for those who are unable to metabolise antipsychotics, is sub-human.  

Useful websites and papers

Clarke C.,  Psychotropic Medications :  Remedies or Poisons? The Evidence from Pharmacogenetics   Asylum Magazine Summer 2010 Volume 17 Number 2

Clarke C.,  Side Effects & Psychopharmacogenetics : Policy-Makers Keep Dodging the Issue Asylum Magazine Autumn 2010 Volume 17 Number 3 

Bray J.,  Clarke C., Brennan G., Muncey T. (2008) 'Should we pushing meds'? The implication of pharmacogenomics  Journal of Psychiatric and Mental Health Nursing Vol.15 No.5 p.357-364     

Super CYP Database:A comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions.Preissner S., Kroll K., Dunkel M., Goldsobel G., Kuzmann D., Senger S., Günther S., Winnenburg R., Schroeder M. and Preissner R.
Nucleic Acids Res 38(Database issue): D237-43. (2010) 


Psychotropic Medication and Cytochromes,  Pharmacological Iatrogenesis, Dr. Yolande Lucire


Includes metaboliser type graph 


Cytochrome P450 Enzymes and Psychopharmacology Sheldon H. Preskorn, M.D. and Anne T. Harvey, Ph.D.